相似文献
1
Two-to-One Randomization: Rarely Advisable.
JCO Oncol Pract. 2024 Dec;20(12):1555-1558. doi: 10.1200/OP.24.00217. Epub 2024 Jul 10.
2
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.
3
Using Mendelian Randomization to Improve the Design of Randomized Trials.
Cold Spring Harb Perspect Med. 2021 Jul 1;11(7):a040980. doi: 10.1101/cshperspect.a040980.
4
Adding experimental arms to platform clinical trials: randomization procedures and interim analyses.
Biostatistics. 2018 Apr 1;19(2):199-215. doi: 10.1093/biostatistics/kxx030.
5
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
6
The effect of framing and communicating COVID-19 vaccine side-effect risks on vaccine intentions for adults in the UK and the USA: A structured summary of a study protocol for a randomized controlled trial.
Trials. 2021 Sep 6;22(1):592. doi: 10.1186/s13063-021-05484-2.
7
Randomization in clinical trials in orthodontics: its significance in research design and methods to achieve it.
Eur J Orthod. 2011 Dec;33(6):684-90. doi: 10.1093/ejo/cjq141. Epub 2011 Feb 14.
8
Outcome--adaptive randomization: is it useful?
J Clin Oncol. 2011 Feb 20;29(6):771-6. doi: 10.1200/JCO.2010.31.1423. Epub 2010 Dec 20.
9
Randomized phase II trials with a prospective control.
Stat Med. 2008 Feb 20;27(4):568-83. doi: 10.1002/sim.2961.
10
Antiviral and immunomodulatory interferon-beta in high-risk COVID-19 patients: a structured summary of a study protocol for a randomised controlled trial.
Trials. 2021 Sep 3;22(1):584. doi: 10.1186/s13063-021-05367-6.
本文引用的文献
1
Efficiency of Biomarker-Driven Clinical Trial Designs.
J Clin Oncol. 2024 Apr 20;42(12):1454-1455. doi: 10.1200/JCO.23.02581. Epub 2024 Mar 4.
2
Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC. Reply.
N Engl J Med. 2024 Jan 25;390(4):381-382. doi: 10.1056/NEJMc2314327.
3
Selpercatinib or Chemotherapy in RET Fusion-Positive NSCLC.
N Engl J Med. 2024 Jan 25;390(4):381. doi: 10.1056/NEJMc2314327.
4
First-Line Selpercatinib or Chemotherapy and Pembrolizumab in Fusion-Positive NSCLC.
N Engl J Med. 2023 Nov 16;389(20):1839-1850. doi: 10.1056/NEJMoa2309457. Epub 2023 Oct 21.
5
Minimization in randomized clinical trials.
Stat Med. 2023 Dec 10;42(28):5285-5311. doi: 10.1002/sim.9916. Epub 2023 Oct 23.
6
Dabrafenib plus Trametinib in Pediatric Glioma with V600 Mutations.
N Engl J Med. 2023 Sep 21;389(12):1108-1120. doi: 10.1056/NEJMoa2303815.
7
FDA Approval Summary: Dabrafenib in Combination with Trametinib for BRAFV600E Mutation-Positive Low-Grade Glioma.
Clin Cancer Res. 2024 Jan 17;30(2):263-268. doi: 10.1158/1078-0432.CCR-23-1503.
8
What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015-2020).
BMJ Open. 2022 Oct 7;12(10):e064458. doi: 10.1136/bmjopen-2022-064458.
9
Augmenting randomized clinical trial data with historical control data: Precision medicine applications.
J Natl Cancer Inst. 2023 Jan 10;115(1):14-20. doi: 10.1093/jnci/djac185.
10
Lutetium-177-PSMA-617 in Metastatic Castration-resistant Prostate Cancer: Limitations of the VISION Trial.
Eur Urol. 2023 Jul;84(1):4-6. doi: 10.1016/j.eururo.2022.08.022. Epub 2022 Sep 9.
Zotero 插件